Dynamic contrast-enhanced MRI for early evaluation of therapeutic response in pancreatic ductal adenocarcinoma
By
Martin D. Holland
Ezinwanne E. Onuoha
Darryl Outlaw
Mehmet Akce
Midhun Malla
Salila Hashmi
Sushanth Reddy
J. Bart Rose
Desiree E. Morgan
Grant R. Williams
Moh’d Khushman
Dana B. Cardin
Katherine Frederick-Dyer
Xiaoyu Jiang
Zarine K. Shah
Bassel El-Rayes
Junzhong Xu
Harrison Kim
August 22, 2026
Clinical Scorecard: Dynamic contrast-enhanced MRI for early evaluation of therapeutic response in pancreatic ductal adenocarcinoma
At a Glance
Category Detail
Condition Pancreatic ductal adenocarcinoma (PDAC) Key Mechanisms Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluates tumor perfusion changes in response to chemotherapy. Target Population Patients with biopsy-confirmed PDAC undergoing chemotherapy. Care Setting Clinical imaging and oncology settings.
Key Highlights
DCE-MRI may identify early perfusion increases in PDAC responding to neoadjuvant chemotherapy. A portable perfusion phantom (P4) improves the reproducibility of DCE-MRI measurements. P4-corrected DCE-MRI outperformed RECIST in differentiating chemotherapy responders from non-responders. Guideline-Based Recommendations
Diagnosis
Biopsy-confirmed PDAC is required for study enrollment. Management
Patients received various chemotherapy regimens including FOLFIRINOX and nab-paclitaxel with gemcitabine. Monitoring & Follow-up
Serum CA19-9 levels were monitored monthly, with imaging assessments performed at specified intervals. Risks
Variability in quantitative DCE-MRI measurements can affect treatment decisions. Patient & Prescribing Data
54 individuals with biopsy-confirmed PDAC.
Chemotherapy response was assessed using RECIST criteria and DCE-MRI measurements.
Clinical Best Practices
Utilize DCE-MRI for early evaluation of therapeutic response in PDAC. Implement P4 for error correction in DCE-MRI to enhance measurement reliability. Related Resources & Content
